Rv 2299c a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice

Han Gyu Choi, Seunga Choi, Yong Woo Back, Seungwha Paik, Hye Soo Park, Woo Sik Kim, Hongmin Kim, Seung Bin Cha, Chul Hee Choi, SungJae Shin, Hwa Jung Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Understanding functional interactions between DCs and antigens is necessary for achieving an optimal and desired immune response during vaccine development. Here, we identified and characterized protein Rv2299c (heat-shock protein 90 family), which effectively induced DC maturation. The Rv2299c-maturated DCs showed increased expression of surface molecules and production of proinflammatory cytokines. Rv2299c induced these effects by binding to TLR4 and stimulating the downstream MyD88-, MAPK- and NF-κB-dependent signaling pathways. The Rv2299cmaturated DCs also showed an induced Th1 cell response with bactericidal activity and expansion of effector/memory T cells. The Rv2299c-ESAT-6 fused protein had greater immunoreactivity than ESAT-6. Furthermore, boosting BCG with the fused protein significantly reduced hypervirulent Mycobacterium tuberculosis HN878 burdens postchallenge. The pathological study of the lung from the challenged mice assured the efficacy of the fused protein. The fused protein boosting also induced Rv2299c-ESAT- 6-specific multifunctional CD4+ T-cell response in the lungs of the challenged mice. Our findings suggest that Rv2299c is an excellent candidate for the rational design of an effective multiantigenic TB vaccine.

Original languageEnglish
Pages (from-to)19947-19967
Number of pages21
JournalOncotarget
Volume8
Issue number12
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Subunit Vaccines
Dendritic Cells
Proteins
Vaccines
T-Lymphocytes
HSP90 Heat-Shock Proteins
Lung
Th1 Cells
Mycobacterium bovis
Mycobacterium tuberculosis
Mycobacterium tuberculosis antigens
Cytokines
Antigens

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Choi, Han Gyu ; Choi, Seunga ; Back, Yong Woo ; Paik, Seungwha ; Park, Hye Soo ; Kim, Woo Sik ; Kim, Hongmin ; Cha, Seung Bin ; Choi, Chul Hee ; Shin, SungJae ; Kim, Hwa Jung. / Rv 2299c a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice. In: Oncotarget. 2017 ; Vol. 8, No. 12. pp. 19947-19967.
@article{c214045d50684b248d6a2bd7dd6fb9f9,
title = "Rv 2299c a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice",
abstract = "Understanding functional interactions between DCs and antigens is necessary for achieving an optimal and desired immune response during vaccine development. Here, we identified and characterized protein Rv2299c (heat-shock protein 90 family), which effectively induced DC maturation. The Rv2299c-maturated DCs showed increased expression of surface molecules and production of proinflammatory cytokines. Rv2299c induced these effects by binding to TLR4 and stimulating the downstream MyD88-, MAPK- and NF-κB-dependent signaling pathways. The Rv2299cmaturated DCs also showed an induced Th1 cell response with bactericidal activity and expansion of effector/memory T cells. The Rv2299c-ESAT-6 fused protein had greater immunoreactivity than ESAT-6. Furthermore, boosting BCG with the fused protein significantly reduced hypervirulent Mycobacterium tuberculosis HN878 burdens postchallenge. The pathological study of the lung from the challenged mice assured the efficacy of the fused protein. The fused protein boosting also induced Rv2299c-ESAT- 6-specific multifunctional CD4+ T-cell response in the lungs of the challenged mice. Our findings suggest that Rv2299c is an excellent candidate for the rational design of an effective multiantigenic TB vaccine.",
author = "Choi, {Han Gyu} and Seunga Choi and Back, {Yong Woo} and Seungwha Paik and Park, {Hye Soo} and Kim, {Woo Sik} and Hongmin Kim and Cha, {Seung Bin} and Choi, {Chul Hee} and SungJae Shin and Kim, {Hwa Jung}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.15256",
language = "English",
volume = "8",
pages = "19947--19967",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

Rv 2299c a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice. / Choi, Han Gyu; Choi, Seunga; Back, Yong Woo; Paik, Seungwha; Park, Hye Soo; Kim, Woo Sik; Kim, Hongmin; Cha, Seung Bin; Choi, Chul Hee; Shin, SungJae; Kim, Hwa Jung.

In: Oncotarget, Vol. 8, No. 12, 01.01.2017, p. 19947-19967.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rv 2299c a novel dendritic cell-activating antigen of Mycobacterium tuberculosis, fused-ESAT-6 subunit vaccine confers improved and durable protection against the hypervirulent strain HN878 in mice

AU - Choi, Han Gyu

AU - Choi, Seunga

AU - Back, Yong Woo

AU - Paik, Seungwha

AU - Park, Hye Soo

AU - Kim, Woo Sik

AU - Kim, Hongmin

AU - Cha, Seung Bin

AU - Choi, Chul Hee

AU - Shin, SungJae

AU - Kim, Hwa Jung

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Understanding functional interactions between DCs and antigens is necessary for achieving an optimal and desired immune response during vaccine development. Here, we identified and characterized protein Rv2299c (heat-shock protein 90 family), which effectively induced DC maturation. The Rv2299c-maturated DCs showed increased expression of surface molecules and production of proinflammatory cytokines. Rv2299c induced these effects by binding to TLR4 and stimulating the downstream MyD88-, MAPK- and NF-κB-dependent signaling pathways. The Rv2299cmaturated DCs also showed an induced Th1 cell response with bactericidal activity and expansion of effector/memory T cells. The Rv2299c-ESAT-6 fused protein had greater immunoreactivity than ESAT-6. Furthermore, boosting BCG with the fused protein significantly reduced hypervirulent Mycobacterium tuberculosis HN878 burdens postchallenge. The pathological study of the lung from the challenged mice assured the efficacy of the fused protein. The fused protein boosting also induced Rv2299c-ESAT- 6-specific multifunctional CD4+ T-cell response in the lungs of the challenged mice. Our findings suggest that Rv2299c is an excellent candidate for the rational design of an effective multiantigenic TB vaccine.

AB - Understanding functional interactions between DCs and antigens is necessary for achieving an optimal and desired immune response during vaccine development. Here, we identified and characterized protein Rv2299c (heat-shock protein 90 family), which effectively induced DC maturation. The Rv2299c-maturated DCs showed increased expression of surface molecules and production of proinflammatory cytokines. Rv2299c induced these effects by binding to TLR4 and stimulating the downstream MyD88-, MAPK- and NF-κB-dependent signaling pathways. The Rv2299cmaturated DCs also showed an induced Th1 cell response with bactericidal activity and expansion of effector/memory T cells. The Rv2299c-ESAT-6 fused protein had greater immunoreactivity than ESAT-6. Furthermore, boosting BCG with the fused protein significantly reduced hypervirulent Mycobacterium tuberculosis HN878 burdens postchallenge. The pathological study of the lung from the challenged mice assured the efficacy of the fused protein. The fused protein boosting also induced Rv2299c-ESAT- 6-specific multifunctional CD4+ T-cell response in the lungs of the challenged mice. Our findings suggest that Rv2299c is an excellent candidate for the rational design of an effective multiantigenic TB vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85015723218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015723218&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15256

DO - 10.18632/oncotarget.15256

M3 - Article

VL - 8

SP - 19947

EP - 19967

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -